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Background: The efficacy of epidural steroid injections in the management of chronic low back pain is disputed,
yet the technique remains popular amongst physicians and patients alike. This study assesses the cost effectiveness
of injections administered in a routine outpatient setting in England.
Methods: Patients attending the Nottingham University Hospitals’ Pain Clinic received two injections of
methylprednisolone plus levobupivacaine at different dosages, separated by at least 12 weeks. Prior to each
injection, and every week thereafter for 12 weeks, participants completed the EQ-5D health-related quality of life
instrument. For each patient for each injection, total health state utility gain relative to baseline was calculated. The
cost of the procedure was modelled from observed clinical practice. Cost effectiveness was calculated as procedure
cost relative to utility gain.
Results: 39 patients provided records. Over a 13-week period commencing with injection, mean quality adjusted
life year (QALY) gains per patient for the two dosages were 0.028 (SD 0.063) and 0.021 (SD 0.057). The difference in
QALYs gained by dosage was insignificant (paired t-test, CIs -0.019 – 0.033). Based on modelled resource use and
data from other studies, the mean cost of an injection was estimated at £219 (SD 83). The cost utility ratio of the
two injections amounted to £8,975 per QALY gained (CIs 5,480 – 22,915). However, at costs equivalent to the tariff
price typically paid to providers by health care purchasers, the ratio increased to £27,459 (CIs 16,779 – 70,091).
Conclusions: When provided in an outpatient setting, epidural steroid injections are a short term, but nevertheless
cost effective, means of managing chronic low back pain. However, designation of the procedure as a day case
requires the National Health Service to reimburse providers at a price which pushes the procedure to the margin of
cost effectiveness.
Trial registration: ISRCTN 43299460Background
Chronic lower back pain has been managed by epidural
steroid injection (ESI) for decades yet the use of the
technique is contentious. On the one hand, recent
reviews of clinical evidence published under the auspices
of authoritative bodies such as the American Pain Soci-
ety [1], the Cochrane Collaboration [2] and the UK’s
Royal College of General Practitioners [3] have con-
cluded that the effectiveness of ESIs remains unproven.
Associated clinical guidelines, such as those of the UK’s
National Institute for Health and Clinical Excellence [4],
explicitly discourage the use of ESIs for non-specific low* Correspondence: david.whynes@nottingham.ac.uk
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reproduction in any medium, provided the orback pain. On the other hand, many pain management
practitioners are robustly critical of such judgments
[5,6]. Some reviewers have interpreted the research find-
ings more positively [7,8], especially with respect to ESI’s
apparent capacity to produce short-term benefits [9-11].
In part, judgments are conditioned by disputes over how
the evidence should be interpreted [12,13].
Even as the scientific controversy over ESIs continues,
the use of the technique in clinical practice proliferates.
In Canada, for example, ESI is the most common pain
procedure amongst anaesthesiologists [14]. In England’s
National Health Service, the annual number of ESI pro-
cedures undertaken increased by 45 per cent between
2000 and 2010 [15], whilst the proportion of the USA
Medicare population receiving an ESI more than
doubled between 1997 and 2006 [16]. These trendsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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back pain over time [17,18] and the likelihood that ESIs
are deemed, at least by a sufficient number of practi-
tioners and patients, to offer benefits.
Given that pain clinics are delivering ESIs for chronic
low back pain in the face of disputed evidence, it would
seem important to establish whether there are grounds
for believing that ESIs offer value for money. In this
paper, we assess the cost effectiveness of ESI. Using data
obtained during a clinical trial, this cohort study com-
pares costs in relation to effects for the same patients,
based on a before-and-after evaluative design. Baseline
data are compared with post-treatment data over a 12-week
follow up period.Method
The Nottingham University Hospitals’ Pain Clinic hosted
a prospective trial of the care of patients with chronic
lower back pain, who were attending for routine repeat
ESI. The principal clinical objective of the study was to
investigate dose–response, by testing the hypothesis that
an injection of methylprednisolone (MPA) 40 mg plus
25 mg levobupivacaine was less effective in ameliorating
short-term (< 3 months) pain-related disability than one
of MPA 80 mg plus 25 mg levobupivacaine. The primary
clinical outcome was the observed change in the
patients’ Oswestry Low Back Pain Disability Index (ODI)
scores, the ODI being a widely-accepted condition-
specific measure used in the management of spinal dis-
orders [19].
Over a six month period, patients were invited to par-
ticipate if they had been scheduled for an ESI at the
Clinic, if they had received 2 or more ESIs in the previ-
ous 12 months, if they were currently experiencing pain
and if their ODI score indicated moderate disability or
worse. The study was conducted as a double-blinded
crossover trial, with each participant receiving one
40 mg and one 80 mg MPA epidural injection in random
order, separated by at least 12 weeks. Immediately prior
to each injection, study participants completed an array
of baseline questionnaires. Patients were then provided
with further multiple copies of the questionnaires and
were instructed to complete the same questionnaire
array every week over the 12 weeks following each injec-
tion. They were permitted to continue all concurrent an-
algesic medications and received weekly telephone
reminders to complete their questionnaires. Patient
exited the study 12 weeks after their second ESI.
In principle, therefore, each participant could complete
26 questionnaire arrays, in the form of two sequences
of 13. Other than dose variation and data-gathering,
patients were managed according to the Clinic’s normal
practices.The study was approved by the Institutional Review
Board, Research Ethics Committee, and the Medicines &
Healthcare Regulatory Authority (MHRA) UK prior to
commencement, and was registered prior to the recruit-
ment of the first participant (ISRCTN 43299460). Mem-
bers of the study team obtained written informed consent
from all study participants prior to randomization in ac-
cordance with the ethical principles that have their origin
in the Declaration of Helsinki and the ICH (International
Conference on Harmonisation) Guideline for Good
Clinical Practice. Full details of the trial’s organization
and its clinical findings have been published elsewhere
[20].
Alongside the ODI, the questionnaire array included
the EQ-5D health-related quality of life instrument [21].
This is a well-validated instrument, widely used for con-
structing the health state utilities which inform cost util-
ity analysis [22]. The EQ-5D questionnaire comprises
two components. First, the subject classifies his or her
health state by indicating the degree of severity of prob-
lem experienced in each of five independent domains.
Any health state so classified can be converted to a sin-
gle utility weight or “index score”, using a set of values
derived from a sample of the general population.
Second, the subject indicates his or her current state on
a visual analogue scale (VAS), within the range “worst
imaginable” to “best imaginable” health state. As the
EQ-5D is a quality of life measure, higher scores imply
higher quality. The nominal range of the EQ-5D index
score is 0–1, but negative scores are possible for health
states deemed to be worse than death. The VAS range is
0–100.
Index scores were calculated from subjects’ EQ-5D
classifications using the UK tariff [23]. The patient’s util-
ity gain or loss consequent upon an injection was
expressed in quality-adjusted life years (QALYs). Longi-
tudinal health state utility gain can be represented as the
area under the curve of index scores against time, rela-
tive to the pre-treatment baseline score [24]. We there-
fore calculated the QALY gain for each patient following
each of the 40 mg and the 80 mg injections as the sum
of the differences between each weekly index score and
the patient’s baseline index score over the 12 week fol-
low-up, divided by 52. A degree of incomplete adherence
to questionnaire completion was anticipated and, where
an index score was missing for a particular week in a se-
quence, it was interpolated from adjacent values. There-
after, we calculated the mean QALY gains from ESI for
each dosage.
Our cost model considered only the resource use of
the health care provider. To calculate the cost of an ESI
in the Pain Clinic, we modeled resource use and trans-
lated this into monetary values using unit resource costs.
Cost estimates published in previous studies provided
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costs were expressed in £UK at 2010 prices. All confi-
dence intervals (CIs) reported subsequently are at 95 per
cent. The incremental cost effectiveness ratio (ICER)
was calculated as the estimated cost of the procedure
relative to utility gains. As unit costs and utilities were
uncorrelated, the estimates of CIs for the ICER were
obtained via Fieller’s method using a proprietary calcula-
tor [25].
Results
Outcomes
Of the 41 patients originally recruited, 37 returned EQ-
5D sequences for both dosages, and a further two sup-
plied a sequence for one dosage only. Eleven patients
returned sequences containing one or more missing
observations, thereby necessitating interpolation. The
interpolation of a single index score was necessary for
eight patients, two scores for another patient and three
scores for a further two. Figure 1 portrays the mean
index and VAS scores for the patients throughout the
sequences. It is evident that, following injection of either
40 mg or 80 mg, health-related quality of life improved
rapidly from baseline (week 0). By week 2, the mean EQ-
5D index score was significantly higher than that at
baseline for both dosages. When patients received the
40 mg and the 80 mg ESIs, the increases in mean index
scores were 0.23 (CIs 0.09 – 0.37) and 0.18 (CIs 0.04 –
0.32), respectively. By week 12, however, index scores
had reverted to baseline: differences between week 0 and
week 12 index scores were insignificant, at 0.01 (CIs
-0.14 – 0.16) and 0.02 (CIs -0.14 – 0.18), respectively.45
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Figure 1 Mean EQ-5D scores.Each of the 13 week-for-week comparisons of mean
index and VAS scores between the 40 mg and 80 mg
dosages revealed an insignificant difference (t-test, all
p = 0.20 or greater). Essentially, the EQ-5D results corro-
borated the inferences which had been made using the
ODI data [20]. The ODI had also detected both
improvements in average short-term health status fol-
lowing ESI under either dosage and an absence of sig-
nificant differences between the week-by-week changes
across the two dosages.
The total QALYs gained over baseline by the patients
over each of the 13-week measurement sequences was,
on average, 0.028 (SD 0.063) when receiving the 40 mg
dose injection and 0.021 (SD 0.057) when receiving the
80 mg dose injection. The difference in QALYs gained
by dosage was insignificant (paired t-test, CIs -0.019 –
0.033). As each patient received one injection at each
dose, the QALYs gained over two treatment episodes
was the sum of the gains from each of the doses. This
amounted to, on average, 0.049 QALYs (SD 0.093).
Costs
The ESI procedure at the Clinic involved an anaesthesi-
ologist (consultant grade) working with two registered
nurses and two care assistants. The procedure was con-
ducted without recourse to fluoroscopic guidance.
Labour costs were derived from national estimates
which included salaries, insurance and pension contribu-
tions, labour-related hospital overheads and capital de-
velopment costs [26]. For the above three grades, these
costs were £169, £47 and £24, respectively, per patient-
contact-hour. Eight patients were routinely scheduled0.45
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of 30 minutes treatment time per patient. As a result, total
labour costs amounted to £156 per ESI.
The cost of disposables used during the procedure,
such as drugs, dressings, gown and cannula, was derived
from an earlier detailed audit of ESIs in the management
of sciatica [27]. As the principal drug employed in that
earlier study differed from that used in this one (MPA),
we substituted the cost of the latter for that of the
former, resulting in a total cost of disposables of £27.
The cost of MPA itself was relatively low (around £5)
and, owing to the standardisation of vial capacity, did
not vary by the size of dose used. Finally, we assigned a
mark-up of 20% on variable costs to cover overheads
such as the use of hospital facilities and utilities. This
proportion follows that used in the sciatica evaluation
but also corresponds closely to the proportion of ex-
penditure devoted to areas other than personnel, clinical
services and supplies in our own hospital [28]. Combin-
ing these components, our model yielded a cost of £219
per ESI delivered.
Modelled costs provide only a single value. To introduce
dispersion around this estimate we searched the literature
for previous cost estimates. The sciatica study, above,
was one of only six which we were able to locate, in
which ESI costs had been presented explicitly. Table 1
provides details of the six studies, including country and
year of cost estimation. In three cases (labeled “tariff”),
the costs of an ESI were those allowable under the
country’s national health insurance scheme. In the
remaining cases, costs resulted from audits of the ESI
procedure (a micro-costing or “bottom-up” approach).
We used the Institute of Education cost converter [29]
to take account of inflation and exchange rates. Our
own cost estimate lay within 4 per cent of the mean of
the six previous values. Adding our model result to the
list of estimates, we calculated a standard deviation of
83 for the seven observations and used this as our dis-
persion parameter for unit cost.
Under its present organizational form, the English
National Health Service (NHS) is divided into careTable 1 Cost estimates
Source Country Date Type Cost
(£UK, 2010cp
[30] Belgium 1999 Tariff 299
[31] Australia 1999 Tariff 196
[32] UK 1999 Audit 94
[27] UK 2002 Audit 189
[33] Netherlands 2005 Audit 153
[34] USA 2007 Tariff 335
Mean of the above 211providers, such as hospitals and clinics, and care purcha-
sers, who hold publicly-supplied funds. Providers are
recompensed by purchasers for services delivered, on
the basis of national tariffs assigned to defined or coded
procedures. The tariff, in other words, is that which the
NHS is obliged to pay for the service, as opposed to that
which the service might cost. That having been said, tar-
iffs are set from reference costs, which are themselves
estimated from the financial returns of individual provi-
ders who are required to employ a standardized
accounting frame. Reference costs depend on the service
definition and context. Most providers in England have
classified an ESI for chronic pain as a “major pain pro-
cedure”, coded AB04Z. Undertaking the procedure as a
“day case” entails formally admitting the patient to the
hospital, treating and discharging within the same day.
The mean reference cost of a day case AB04Z was £670
(SD 248), subject to local variations [35]. However, the
procedure can also be delivered on an outpatient basis,
whereby the patient attends for treatment but is not ad-
mitted. The mean reference cost for outpatient AB04Z
was £145 (SD 101). Nearly 89,000 AB04Z procedures
were performed in English hospitals in 2010–11, around
94 per cent of which were day cases.
Cost-utility
From the above, the average patient receiving two ESIs
at different dosages incurred modeled costs of £438 (SD
166) for an expected gain of 0.049 QALYs (SD 0.093).
When combined, these estimates for outcome and cost
produced an ICER of £8,975 per QALY gained (CIs
5,480 – 22,915) for an “average” ESI plus analgesics
compared with analgesics alone. This placed the inter-
vention below the current threshold for cost effective-
ness in England, namely, the range £20-30,000 per
QALY gained [36]. Replacing the modeled cost estimate
with the reference cost for delivery in an outpatient set-
ting caused the ICER to fall £5,943 (CIs 3,462 – 15,338),
thereby making the intervention appear even more cost
effective. Replacing the modeled cost estimate with the
reference cost for ESI as a day case caused the ICER to
rise to £27,459 (CIs 16,779 – 70,091). This mean value is
at the upper end of the acceptable range for cost effect-
iveness in the English NHS.
Discussion
As assessed using the EQ-5D instrument, patients evi-
dently followed an “inverted-U-shaped” quality of life
path over time (Figure 1). This is consistent with the
paths reported in previous observational studies, al-
though these studies used pain-specific outcome mea-
sures and recorded less frequently [37,38]. The effect
was reported to be greatest up to 4 weeks following in-
jection, with progressive reduction in impact in the
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a dosage trial [39].
Comparisons between our estimates and those from
two ESI pain trials are instructive. The PINE trial in the
Netherlands [40] included around 600 patients with
acute herpes zoster. As with our own study, it compared
analgesics only with analgesics plus ESI using MPA.
Even though it measured short term EQ-5D outcomes
less frequently, at 4 weeks and at 12 weeks only, the
reported trend in outcome was similar. Compared with
analgesics only, ESI improved index scores significantly
at 4, but not at 12, weeks. However, at an estimated 0.01
QALYs gained per patient [33], the net health gain was
smaller than for our subjects. By way of explanation for
the difference, the PINE measurement schedule was less
intensive. More widely spaced readings imply less preci-
sion and would result in undervaluation if, as our study
has concluded, noticeable benefits begin to accrue al-
most immediately after injection. Also, the PINE
patients’ conditions were acute rather than chronic and
their baseline EQ-5D-measured quality of life was higher
than that of our patients. Their pain was less severe, and
it would seem probable that the marginal benefit of ESI
is lower when pre-intervention quality of life is higher.
An English trial of multiple ESIs for sciatica included
around 230 patients [27]. As with the PINE study, these
were assessed twice only in the short term, at 3 and at
6 weeks. Against a placebo saline injection, the estimated
health gain was even smaller, at 0.006 QALYs per pa-
tient, and almost all this accrued at 3 weeks. Again by
way of explanation, quality of life outcomes for the sciat-
ica trial were measured using the SF36 instrument,
translated to the SF-6D and its associated utilities. There
is robust evidence from parallel instrumentation studies
that, for a given health improvement, the utility gain
when measured using the SF-6D is significantly smaller
than when measured by the EQ-5D [41]. Also, and un-
like our patients, the sciatica patients were a mixture of
chronic and acute, and the health gain amongst the
acute patients was smaller. Finally, the sciatica trial was
not so much a trial of the procedure as of the active in-
gredient, because all subjects received an injection.
A common feature of both of these previous trials was
that the subjects had no record of successful treatment
by ESI. Indeed, previous receipt of an ESI for pain was
an explicit exclusion criterion for the sciatica trial. In
contrast, all our patients had received ESIs at the Pain
Clinic on previous occasions. One of the few areas of
agreement in the debate over the efficacy of ESIs is that
not all people experiencing chronic back pain respond
to treatment. It therefore follows that differential bias in
recruitment must also contribute to explaining the dif-
ferences in findings. Trials requiring subjects to have no
experience of ESI in pain relief are more likely to recruitpeople for whom the technique will prove ineffectual,
thereby lowering the average health gain recorded. In
contrast, the clientele of any clinic offering routine care
will be dominated by patients for whom the treatment is
efficacious. Many of the patients unresponsive to ESI,
therefore, would have discontinued treatment prior to
being recruited into our study.
Combining all this information, there appear good
grounds for suspecting the presence of a placebo effect
within ESI’s overall treatment effect. Patient-reported
outcomes in both the PINE study [33] and our own indi-
cated that ESI produced significant patient-reported
short-term health gains, on average. However, both the
sciatica study [27] and our own suggested that the mar-
ginal impact of the active ingredient in the injection
might have been small. The sciatica study detected only
modest gains from an active injection compared with a
saline placebo, and others have reported similarly [42].
We identified no significant differences in utilities fol-
lowing ESIs with different dosages. Identifying the mag-
nitude of the placebo effect itself could prove difficult. It
would require a trial with two randomisations rather
than one, namely, between injection and “no treatment”
and between active and placebo ingredients. In fact, such
a design has already been rejected in the studies cited,
although with different objections. Whilst the sciatica
investigators deemed it unethical to include a “no treat-
ment” arm, the PINE investigators considered a placebo
arm to be unethical. Ethical considerations aside, such a
trial might fail to recruit, on the expectation that few
patients would risk randomisation away from a well-
established (if not well-proven) treatment.
This study has demonstrated cost effective quality of
life gains from two ESI episodes over a six month
period. How this practice might fit into a longer term
management scenario remains unclear, both from this
study and from others. In the absence of further injec-
tions, for example, patients’ symptoms could eventually
stabilise at or above the pre-injection baseline or, alter-
natively, deteriorate to poorer states of health. Both
results have been reported [43,44]. Were injections to be
repeated regularly over the longer term, it is unclear
whether each subsequent ESI would produce the same
effect as its predecessor or whether diminishing returns
would prevail. It is probable that a belief in a repeated
benefit influences contemporary practice; a survey of US
anaesthesiologists revealed that the average maximal
number of ESIs per patient was in excess of four per
year [45]. In spite of the popularity of serial injection,
however, a review found only limited, and contradictory,
evidence for offering patients repeated ESIs [46].
We noted that our results permitted different interpre-
tations of the ICER, depending on whether costs were
modelled from estimates of resource use or assessed at
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elled costs, the ICER using day case reference costs was
around 3.4-times higher, and the ICER using outpatient
reference costs was around two-thirds lower. The two
other studies reported a similar phenomenon but with
even more extreme disparities. The protocol of the Eng-
lish sciatica study allowed for multiple injections to be
carried out [27]. The NHS tariff cost of the regimen spe-
cified by the protocol was 7.9-times greater than the
costs estimated from measured resource use, with corre-
sponding implications for the ICER. In the PINE study,
the ICER based on the tariffs for ESIs allowed by the
Netherlands insurance companies’ reimbursement
scheme was 4.6-times higher than that estimated using
the observed costs of the procedures [33]. The authors
concluded that the balance of cost effectiveness tipped
as the divergence between tariff and resource cost
increased, and the conclusions from our own study are
essentially equivalent.
How a procedure is classified for reimbursement is
more a matter of accounting than of clinical practice. In
this context, the Audit Commission, which monitors ef-
ficiency in public spending, has recently commented on
the inconsistent classification of short-term treatments
throughout the NHS [47]. It concludes that discrepan-
cies between hospitals arise less from lack of clarity in
guidance (although this is certainly present) and more
from financial incentives. As outpatient treatment is
usually recompensed at a lower tariff than day case
treatment, many providers choose to provide essentially
the same service and designate it as the latter rather
than as the former. The Audit Commission notes that
the NHS is therefore paying far more for services than
might otherwise be necessary and that inaccuracies are
being introduced into procedures’ estimated reference
costs. We would add that, according to our ESI study,
the designated setting of service delivery could prove
significant in determining whether or not a procedure
could be considered unequivocally cost effective.
Cost of illness studies [48] generally demonstrate that
the direct costs of treating back pain are less than the in-
direct costs of the condition. These include both
absences from work resulting in lost production and
decreased productivity on the part of those who con-
tinue working despite being in pain. As we measured
only health gains and the direct costs of treatment in
this study, the contribution of ESIs to reducing the non-
NHS costs of back pain has not been accounted for.
However, we would suppose that pain reduction effected
by an ESI would, at worst, have no effect on absence
from work and productivity losses, and it might well re-
duce them. To complete the ICER calculation from a so-
cial perspective, therefore, the direct costs of treatment
would have to be partially offset by reductions in theindirect costs of pain. By implication, the ICERs we have
estimated represent maximum values. Evaluated from a
social perspective, the ICERs would be lower than those
presented earlier, i.e. the procedure would be judged
more, rather than less, cost effective.
Conclusions
Although the efficacy of epidural steroid injections is the
subject of debate, the technique is widely-used. Our
study indicates short term effectiveness in improving
health-related quality of life. Our results suggest that
steroid injections can be a cost effective means of managing
chronic low back pain. However, designation of the pro-
cedure as a day case is likely to require the National Health
Service to reimburse providers at a price which pushes the
procedure to the margin of cost effectiveness.
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